You are here: Industry Insights > Market News > Cannabics Concludes Pre-Clinical Study on Human Biopsies

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

3-Bromo-4-fluorobenzaldehyde

5-Methyl-1,3,4-oxadiazol2(3H)-one

4-Amino-6-methyl-3 oxo2,3, 4,5-tetrahydro 1.2.4-triazine hydrochloride

4-Acetylamino-6-methyl -3-oxo-2,3,4,5-tetrahydro-1,2,4-triazine

3-Pyridinecarboxaldehyde

Ethyl 3 Fluorobenzoate

Cannabics Concludes Pre-Clinical Study on Human Biopsies

americanpharmaceuticalreviewNovember 19, 2020

Tag: Cannabics , RCC-33 , Tumor , human biopsies

Favorites

Cannabics Pharmaceuticals has completed a pre-clinical study using its proprietary and novel RCC-33 formulation on human biopsies, obtained under a Helsinki Committee approved protocol. The results show an antitumor synergistic effect of the active compounds, thus confirming the company' previously obtained data on the antitumor properties of the drug candidate when screened on colorectal cell lines.

"The study results brings us one step closer in preparing our submission to the U.S. Food and Drug Administration for a pre-IND meeting. Our next step will be launching a study on mice to try and demonstrate the same synergistic effect and see tumor growth attenuation in-vivo," Dr. Eyal Ballan, Cannabics Pharmaceuticals' CTO said.

Previous:Impel Neuropharma Announces FDA NDA Submission of INP104 for Migraine

Next:ViiV’s cabotegravir scores breakthrough designation for HIV prevention

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

BioPharmaSpec, the leading global Contract Research Organization (CRO) for Discovery and Preclinical Characterization of Biopharmaceuticals, has officially announced three new European facilities.

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Cannabics Concludes Pre-Clinical Study on Human Biopsies | Pharmasources.com

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

PharmaSourcesNovember 15, 2024

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

You may like
More>>

Recombinant Murine Tumor Necrosis Factor Receptor I/Tumor Necrosis Factor Receptor Superfamily 1A

Recombinant Human Tumor Necrosis Factor Receptor I/Tumor Necrosis Factor Receptor Superfamily 1A

Recombinant Human Tumor Necrosis Factor Receptor II/Tumor Necrosis Factor Receptor Superfamily 1B

chamomile flower extract, Apigenin ,520-36-5,Apigenin powder,Chamomile powder,anti-tumor

Recombinant Rhesus Tumor Necrosis Factor-alpha

Recombinant Human Tumor Necrosis Factor-alpha

Recombinant Rat Tumor Necrosis Factor-alpha

Recombinant Human AITR Ligand/Tumor Necrosis Factor Superfamily Member 18

Recombinant Murine Tumor Necrosis Factor Receptor II/Tumor Necrosis Factor Receptor Superfamily 1B

Recombinant Human Fas Receptor/Tumor Necrosis Factor Receptor Superfamily 6

Cannabics Concludes Pre-Clinical Study on Human Biopsies

Related News

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

You may likeMore>>

You may like
More>>